Related Experiment Videos
Overcoming resistance to imatinib by combining targeted agents
1Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA.
Molecular Cancer Therapeutics
|March 27, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Identifying Drug Combination Strategies for ZMYM2: FGFR1 Fusion Positive Leukemia.
Precision oncogenomics·2025
Sensitivity of pancreatic adenocarcinoma cells to blockade of post-initiation CDK-dependent Pol II transcription cycle checkpoints.
Molecular cancer therapeutics·2026
Dual Targeting of EGFR and HER2 by a Bispecific Antibody-Drug Conjugate Demonstrates Broad Antitumor Activity in Multiple Solid Tumors.
Molecular cancer therapeutics·2026
Anti-tumor activity of orally available cyclic peptide LUNA18 through direct pan-RAS inhibition across diverse RAS genetic alterations.
Molecular cancer therapeutics·2026
AZ'4331 is a novel pan-TEAD auto-palmitoylation inhibitor for the treatment of Hippo pathway-altered cancers.
Molecular cancer therapeutics·2026
Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer.
Molecular cancer therapeutics·2026